Your browser doesn't support javascript.
loading
Integrated molecular and pharmacological characterization of patient-derived xenografts from bladder and ureteral cancers identifies new potential therapies.
Lang, Hervé; Béraud, Claire; Cabel, Luc; Fontugne, Jacqueline; Lassalle, Myriam; Krucker, Clémentine; Dufour, Florent; Groeneveld, Clarice S; Dixon, Victoria; Meng, Xiangyu; Kamoun, Aurélie; Chapeaublanc, Elodie; De Reynies, Aurélien; Gamé, Xavier; Rischmann, Pascal; Bieche, Ivan; Masliah-Planchon, Julien; Beaurepere, Romane; Allory, Yves; Lindner, Véronique; Misseri, Yolande; Radvanyi, François; Lluel, Philippe; Bernard-Pierrot, Isabelle; Massfelder, Thierry.
Afiliación
  • Lang H; Department of Urology, New Civil Hospital and Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France.
  • Béraud C; Urosphere, Toulouse, France.
  • Cabel L; Institut Curie, Centre National de la Recherche Scientifique (CNRS), UMR144, Molecular Oncology team, PSL Research University, Paris, France.
  • Fontugne J; Sorbonne Universités, Université Pierre-et-Marie-Curie (UPMC), Univ Paris, Paris, France.
  • Lassalle M; Institut Curie, Centre National de la Recherche Scientifique (CNRS), UMR144, Molecular Oncology team, PSL Research University, Paris, France.
  • Krucker C; Department of Pathology, Institut Curie, Saint-Cloud, France.
  • Dufour F; Université de Versailles-Saint-Quentin-en-Yvelines (UVSQ), Paris-Saclay University, Versailles, France.
  • Groeneveld CS; Urosphere, Toulouse, France.
  • Dixon V; Institut Curie, Centre National de la Recherche Scientifique (CNRS), UMR144, Molecular Oncology team, PSL Research University, Paris, France.
  • Meng X; Sorbonne Universités, Université Pierre-et-Marie-Curie (UPMC), Univ Paris, Paris, France.
  • Kamoun A; Department of Pathology, Institut Curie, Saint-Cloud, France.
  • Chapeaublanc E; Institut Curie, Centre National de la Recherche Scientifique (CNRS), UMR144, Molecular Oncology team, PSL Research University, Paris, France.
  • De Reynies A; Sorbonne Universités, Université Pierre-et-Marie-Curie (UPMC), Univ Paris, Paris, France.
  • Gamé X; Inovarion, Paris, France.
  • Rischmann P; Institut Curie, Centre National de la Recherche Scientifique (CNRS), UMR144, Molecular Oncology team, PSL Research University, Paris, France.
  • Bieche I; Sorbonne Universités, Université Pierre-et-Marie-Curie (UPMC), Univ Paris, Paris, France.
  • Masliah-Planchon J; La Ligue Contre Le Cancer, Paris, France.
  • Beaurepere R; Institut Curie, Centre National de la Recherche Scientifique (CNRS), UMR144, Molecular Oncology team, PSL Research University, Paris, France.
  • Allory Y; Sorbonne Universités, Université Pierre-et-Marie-Curie (UPMC), Univ Paris, Paris, France.
  • Lindner V; Department of Pathology, Institut Curie, Saint-Cloud, France.
  • Misseri Y; Institut Curie, Centre National de la Recherche Scientifique (CNRS), UMR144, Molecular Oncology team, PSL Research University, Paris, France.
  • Radvanyi F; Sorbonne Universités, Université Pierre-et-Marie-Curie (UPMC), Univ Paris, Paris, France.
  • Lluel P; Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China.
  • Bernard-Pierrot I; La Ligue Contre Le Cancer, Paris, France.
  • Massfelder T; Institut Curie, Centre National de la Recherche Scientifique (CNRS), UMR144, Molecular Oncology team, PSL Research University, Paris, France.
Front Oncol ; 12: 930731, 2022.
Article en En | MEDLINE | ID: mdl-36033544
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Oncol Año: 2022 Tipo del documento: Article País de afiliación: Francia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Oncol Año: 2022 Tipo del documento: Article País de afiliación: Francia